attomarker

Precision Diagnostics for a Personalised Future

Helping you turn science into medicine through next-generation, multiplexed blood testing.
Explore COVID Antibody Spectrum TestFor Physicians

CE Marked Technology Platform

Licensed under UK CA Mark

Developed with University of Exeter

Turning Science Into Medicine

Our platform measures multiple biomarkers simultaneously, quantitatively, and with precision. In Long COVID, this already allows us to characterise three distinct endotypes, each requiring a different approach to care.

Built on years of translational research from the University of Exeter, Attomarker technology integrates gold particle nanotechnology, microfluidics, multiplexing and data analytics.

True Multiplexing

Simultaneous measurement of multiple biomarkers.

Quantitative Precision

Track target levels with calibrated accuracy.

Clinical Validation

Licensed and ready for professional use.

Explore Our Technology

COVID Antibody Spectrum Test

Licensed under UK CA Mark

Advanced multiplex test that measures antibody quantity and quality across 15 COVID-19 variants to provide an informative window into the immune system of Long COVID patients, including classification of their endotype into hypoimmune, hyperimmune or universal responder. This can help guide appropriate and personalised therapeutic choices.

Licensed and approved under UKCA

Quantitative measurement of antibody levels

Quantitative assessment of antibody functional quality

Identifies immune subtypes

Supports informed treatment & vaccination decisions

Explore COVID Antibody Spectrum Test
A smiling woman applies a Tasso blood lancet device to her upper arm for a simple, at-home capillary blood collection.

Personalised Care – The Endotype Imperative

We have shown that immune responses vary dramatically between individuals with Long COVID.

Recognising these endotypes or biological subtypes of immune behaviour, is essential to personalised care and appropriate treatment choices.

Hyperimmune:

over-active antibody responses that may drive inflammation.

Hypoimmune:

weak or absent antibody responses needing targeted support.

Universal Responders:

where immune profile or response is more comprehensive.

Just like in cancer treatment, each endotype requires a different therapeutic approach, tailored to that endotype.

Understand Immune Endotypes in Long COVID

Our Expanding Pipeline

Attomarker’s multiplex platform is designed to scale across disease areas, initially focused on immunology, infection and inflammation, but applicable in many other areas of precision diagnostics and personalised medicine are beneficial.

Immunology & Infectious Diseases
Other Applications

Spike Protein Test – evaluation of immune effects of virus versus mRNA vaccine technology.

Infection Spectrum Test – differentiating viral from bacterial infection at point of care.
Click to view test »

Latest News & Insights

Stay up to date with new research, validation studies, and industry developments from Attomarker’s scientists and partners.

Who We Serve

Patients & Individuals

Access licensed testing to understand your immune recovery.

Clinicians & Researchers

Gain actionable, quantitative immune data to inform care strategies.

Commercial & Clinical Partners

Collaborate to expand global access to multiplex diagnostics.

Investors

Join us in scaling the next generation of precision diagnostics.

In Long COVID, Your Immune System Has a Story

We Help You Read It
Understand your immune endotype, which can help guide treatment choices and recovery.
Order the Covid Antibody Spectrum Test
Contact Attomarker